IONIS PHARMACEUTICALS INC — Director's Dealing 2019

Apr 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2019-04-03

Reporting Person: O'NEIL PATRICK R. (SVP Legal & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-04-03	Common Stock	M	7654	$61.68	Acquired	27327	Direct
2019-04-03	Common Stock	S	7654	$84.83	Disposed	19673	Direct
2019-04-04	Common Stock	M	15492	$61.68	Acquired	35165	Direct
2019-04-04	Common Stock	S	15492	$84.75	Disposed	19673	Direct
2019-04-04	Common Stock	M	4873	$61.68	Acquired	24546	Direct
2019-04-04	Common Stock	S	4873	$82.19	Disposed	19673	Direct
2019-04-04	Common Stock	M	2657	$61.57	Acquired	22330	Direct
2019-04-04	Common Stock	S	2657	$82.03	Disposed	19673	Direct
2019-04-04	Common Stock	M	2000	$47.34	Acquired	21673	Direct
2019-04-04	Common Stock	S	2000	$84.20	Disposed	19673	Direct
2019-04-04	Common Stock	M	3600	$47.34	Acquired	23273	Direct
2019-04-04	Common Stock	S	3600	$82.10	Disposed	19673	Direct
2019-04-04	Common Stock	M	8000	$49.25	Acquired	27673	Direct
2019-04-04	Common Stock	S	8000	$84.29	Disposed	19673	Direct
2019-04-04	Common Stock	S	1122	$82.01	Disposed	18551	Direct
2019-04-04	Common Stock	S	1878	$84.25	Disposed	16673	Direct
2019-04-05	Common Stock	M	2252	$61.68	Acquired	18925	Direct
2019-04-05	Common Stock	S	2252	$84.75	Disposed	16673	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-03	Employee Stock Option (right to buy)	$61.68	M	7654	Acquired	2023-01-03	Common Stock (7654)	Direct
2019-04-04	Employee Stock Option (right to buy)	$61.68	M	20365	Acquired	2023-01-03	Common Stock (20365)	Direct
2019-04-04	Employee Stock Option (right to buy)	$61.57	M	2657	Acquired	2022-01-01	Common Stock (2657)	Direct
2019-04-04	Employee Stock Option (right to buy)	$47.34	M	5600	Acquired	2024-01-02	Common Stock (5600)	Direct
2019-04-04	Employee Stock Option (right to buy)	$49.25	M	8000	Acquired	2025-01-01	Common Stock (8000)	Direct
2019-04-05	Employee Stock Option (right to buy)	$61.68	M	2252	Acquired	2023-01-03	Common Stock (2252)	Direct

Footnotes

F1: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 8/29/2018.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.025, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 8/29/2018 and 3/5/2019.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

F5: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/5/2019.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.05, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.20 to $84.35, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) on this Form 4.

F8: The sale was made pursuant to shares owned.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.02, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) on this Form 4.